title: Autoimmune hemolytic anemia during adalimumab treatment for plaque psoriasis.
abstract: Adalimumab is commonly used to treat autoimmune diseases with few reported hematological adverse reactions. We herein describe the case of an 85-year-old Japanese man with plaque psoriasis who developed autoimmune hemolytic anemia (AIHA) after 3 years of adalimumab treatment. The patient suddenly developed hematuria and dyspnea on exertion while receiving adalimumab treatment. Laboratory data showed low hemoglobin levels and slightly increased reticulocyte counts, while direct and indirect antiglobulin tests were positive. The patient was diagnosed with AIHA which resolved after replacing the adalimumab treatment with prednisolone therapy. The findings from this case indicate that AIHA may be caused by long-term adalimumab treatment.
authors.affiliation: Nagano Chuo Hospital, Japan.
authors.forename: Yukinori
authors.initials: Y
authors.lastname: Harada
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Yamamoto
authors.forename: Midori
authors.initials: M
authors.lastname: Sato
authors.forename: Mutsuki
authors.initials: M
authors.lastname: Kodaira
authors.forename: Tsunesuke
authors.initials: T
authors.lastname: Kono
mesh_terms: D000068879:Adalimumab; D000369:Aged, 80 and over; D000744:Anemia, Hemolytic, Autoimmune / Q000139:chemically induced* / Q000175:diagnosis; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D003298:Coombs Test; D004417:Dyspnea / Q000139:chemically induced*; D006417:Hematuria / Q000139:chemically induced*; D006801:Humans; D008297:Male; D011239:Prednisolone / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy*
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D011239:Prednisolone; D000068879:Adalimumab